Identification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease.
Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Jun 11, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The MICROSPA trial is studying the differences in gut bacteria and other substances in the blood and immune system of patients with Crohn's disease, particularly those who also have a related condition called spondyloarthritis. Researchers want to understand how these factors might be linked to Crohn's disease and spondyloarthritis by comparing three groups: patients with only Crohn's disease, patients with only spondyloarthritis, and those who have both conditions. They will also look at a group of healthy individuals for comparison.
To qualify for this study, participants must be at least 18 years old and fall into one of the three patient groups mentioned. They cannot have had certain medical procedures, like colon surgery, or be on specific medications that could affect the study results. If you decide to participate, you'll provide a stool sample and some blood for testing. This could help researchers identify potential biomarkers, which are indicators that could lead to better understanding and treatment of these conditions in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years.
- * Patients will be recruited according to 3 groups:
- • Patients with Crohn's disease and axial spondyloarthritis according to the criteria below.
- • Patients with Crohn's disease (MC patients) with a diagnosis established according to clinical, biological criteria, radiological, endoscopic and / or histological studies for 3 months. With diagnosis of exclusion of a spondyloarthritis on criteria ASAS and / or New York modified.
- • Patients with axial spondyloarthritis (SpA patients) with a diagnosis based on modified ASAS and / or New York criteria with exclusion diagnosis of Crohn's disease.
- • Patient with the ability to give free and express informed consent.
- Exclusion Criteria:
- • History of colonic resection
- • Taking antibiotics or colon preparation for colonoscopy within 8 weeks before stool collection (Temporary contraindication = removal possible before colic or first bowel preparation after the start of colonic preparation).
- • Ostomy at the time of sampling
- • BMI\> 30
- • extreme diet
- • unbalanced diabetes
- • Pregnant woman
- • Patient under guardianship, under curatorship or under the protection of justice Contacts/Locations Central Contact
About Central Hospital, Nancy, France
Central Hospital, located in Nancy, France, is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes. As a prominent clinical trial sponsor, the hospital is committed to conducting innovative studies across various therapeutic areas, fostering collaboration among multidisciplinary teams of healthcare professionals and researchers. With a strong emphasis on ethical standards and patient safety, Central Hospital leverages its state-of-the-art facilities and expertise to contribute to the development of cutting-edge treatments and enhance the overall quality of care within the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Nancy, Lorraine, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials